Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease

CNS Drugs

Volumn 22, Issue 7, 2008, Pages 563-586

  Gallagher, David A ^a,b   Schrag, Anette ^a,b,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiparkinsonians, therapeutic use; Catechol O methyltransferase inhibitors, therapeutic use; Dopamine D2 receptor agonists, therapeutic use; Dopamine receptor agonists, therapeutic use; Entacapone, therapeutic use; Levodopa, therapeutic use

Indexed keywords

BENSERAZIDE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SERTRALINE; TOLCAPONE;

ADD ON THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG METABOLISM; DYSKINESIA; EATING DISORDER; HALLUCINATION; HUMAN; HYPERSEXUALITY; LUNG FIBROSIS; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; OUTCOMES RESEARCH; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PLEURAL FIBROSIS; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; VALVULAR HEART DISEASE; VISUAL HALLUCINATION; VOMITING;

ANTIPARKINSON AGENTS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 44949178691     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822070-00003     Document Type: Review

References (165)

1. Bennett MC. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 2005; 105: 311-31
2. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease Nat Rev Drug Discov. 2006; 5: 845-54
3. Braak H, Del Tredici JK, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 Suppl. 3: III/1-5
4. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-81
5. Siegel JM. The stuff dreams are made of: anatomical substrates of REM sleep. Nat Neurosci 2006; 9: 721-2
6. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006; 248: 255-8
7. Williams-Gray CH, Foltynie T, Lewis SJ, et al. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006; 20: 477-505
8. Braak H, Bohl JR, Muller CM, et al. Stanley Fahn lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21: 2042-51
9. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 38 Suppl. 2: 2-7
10. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42: 726-32
11. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne BD, et al., editors. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Healthcare Information, 1987: 153-64
12. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53
13. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101
14. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58
15. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63: 1756-60
16. Biglan KM, Holloway Jr RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Parkinson Study Group CALM-PD Investigators. Neurology 2007; 69: 187-95
17. Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005; 62: 1242-8
18. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-73
19. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46
20. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007; 22: 1-9
21. Raudino F. Nonmotor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312-5
22. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. EXPRESS Investigators. Mov Disord 2006; 21: 456-61
23. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-16
24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42
25. Schwab RS, England Jr AC. Projection techniques for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, editors. Third symposium on Parkinson's disease, Royal College of Surgeons, 1968 May 20-22. Edinburgh: E&S Livingstone Ltd, 1969: 152-7
26. Wheatley K, Stowe RL, Clarke CE, et al. Evaluating drug treatments for Parkinson's disease: how good are the trials? BMJ 2002; 324: 1508-11
27. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000; 23 (1): 34-44
28. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22: 41-7
29. Shulman LM, Taback RL, Rabinstein AA, et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 193-7
30. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007; 22: 1901-11
31. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 2007; 22: 1528-37
32. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006; 248: 151-7
33. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241-8
34. Jenkinson C, Fitzpatrick R. Cross-cultural evaluation of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8): results from America, Canada, Japan, Italy and Spain. Parkinsonism Relat Disord 2007; 13: 22-8
35. Welsh M, McDermott MP, Holloway RG, et al. Development and testing of the Parkinson's disease quality of life scale. Parkinson Study Group. Mov Disord 2003; 18: 637-45
36. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson's disease with the Parkinson's disease quality of life questionnaire. Age Ageing 1999; 28: 341-6
37. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551-9
38. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
39. Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile: development of an outcome measure of health care. Am J Public Health 1975; 65: 1304-10
40. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60-7
41. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease: a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord 2005; 11: 465-8
42. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-30
43. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Trial Study Group. Eur J Neurol 2005; 12 (12): 956-63
44. Michalowska M, Fiszer U, Krygowska-Wajs A, et al. Falls in Parkinson's disease: causes and impact on patients' quality of life. Funct Neurol 2005; 20: 163-8
45. Moore O, Peretz C, Giladi N. Freezing of gait affects quality of life of peoples with Parkinson's disease beyond its relationships with mobility and gait. Mov Disord 2007; 22: 2192-5
46. Gomez-Esteban JC, Zarranz JJ, Lezcano E, et al. Influence of motor symptoms upon the quality of life of patients with Parkinson's disease. Eur Neurol 2007; 57: 161-5
47. Miller N, Noble E, Jones D, et al. Hard to swallow: dysphagia in Parkinson's disease. Age Ageing 2006; 35: 614-8
48. Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other non-motor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52: 784-8
49. Yoshii F, Takahashi H, Kumazawa R, et al. Parkinson's disease and fatigue. J Neurol 2006 Dec; 253 Suppl. 7: vii48-53
50. Martinez-Martin P, Catalan MJ, Benito-Leon J, et al. Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS). Qual Life Res 2006; 15: 597-606
51. Bronner G, Royter V, Korczyn AD, et al. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 2004; 30: 95-105
52. Moore O, Gurevich T, Korczyn AD, et al. Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 243-6
53. Swinn L, Schrag A, Viswanathan R, et al. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18: 1459-63
54. Scaravilli T, Gasparoli E, Rinaldi F, et al. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci 2003; 24: 209-10
55. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001; 92: 76-85
56. Kashihara K. Weight loss in Parkinson's disease. J Neurol 2006; 253 Suppl. 7: vii38-41
57. Suzukamo Y, Ohbu S, Kondo T, et al. Psychological adjustment has a greater effect on health-related quality of life than on severity of disease in Parkinson's disease. Mov Disord 2006; 21: 761-6
58. Shimbo T, Goto M, Morimoto T, et al. Association between patient education and health-related quality of life in patients with Parkinson's disease. Qual Life Res 2004; 13: 81-9
59. Kuopio AM, Marttila RJ, Helenius H, et al. The quality of life in Parkinson's disease. Mov Disord 2000; 15: 216-23
60. Karlsen KH, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66: 431-5
61. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-12
62. Carod-Artal FJ, Vargas AP, Martinez-Martin P. Determinants of quality of life in Brazilian patients with Parkinson's disease. Mov Disord 2007 July 30; 22 (10): 1408-15
63. Marras C, McDermott MP, Rochon PA, et al. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Parkinson Study Group DATATOP Investigators. Mov Disord 2008; 23: 653-9
64. Greene T, Camicioli R. Depressive symptoms and cognitive status affect health-related quality of life in older patients with Parkinson's disease. J Am Geriatr Soc 2007; 55: 1888-90
65. McKinlay A, Grace RC, Dalrymple-Alford JC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord 2008; 14: 37-42
66. Beck AT, Steer RA, Ball R, et al. Comparison of Beck depression inventories-IA and -II in psychiatric outpatients. J Pers Assess 1996; 67: 588-97
67. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: a standardised instrument for the diagnosis of mental disorder in the elderly, with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698-709
68. Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res 2002; 11: 263-72
69. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17 (1): 37-49
70. Sheikh JA, Yesavage JA. Geriatric depression scale (GDS): recent findings and development of a shorter version. In: Brink TL, editor. Clinical gerontology: a guide to assessment and intervention. New York. Howarth Press, 1986
71. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67 (6): 361-70
72. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
73. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-92
74. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
75. Hunt SM, McKenna SP, McEwen J, et al. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980; 34: 281-6
76. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat 1968; 5: 257-82
77. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70
78. Dewey II RB, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007; 64: 377-80
79. Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord 2007; 22 (6): 757-65
80. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22 (16): 2409-17
81. Grandas F, Hernandez B. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. The PRACTICOMT Study Group. Eur J Neurol 2007; 14: 282-9
82. Reichmann H, Boas J, Macmahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. The ComQol Study Group. Acta Neurol Scand 2005; 111: 21-8
83. Lyons KE, Pahwa R. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (Stalevo) in Parkinson disease patients. Clin Neuropharmacol 2006; 29: 73-6
84. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson s disease. Neurodegener Dis 2008; 5 (3-4): 244-6
85. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41: 261-309
86. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 2000; 55 (11 Suppl. 4): S33-7
87. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004; (4): CD004554
88. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria. Celomen Study Group. Acta Neurol Scand 2002; 105: 245-55
89. Myllylä VV, Kultalahti ER, Haapaniemi H, et al. Twelve-month safety of entacapone in patients with Parkinson's disease. The FILOMEN Study Group. Eur J Neurol 2001; 8: 53-60
90. Parkinson's Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-55
91. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in Parkinsonian patients with motor fluctuations. The Nomecomt Study Group. Neurology 1998; 51: 1309-14
92. Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in Parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. The TC-INIT Study Group. Eur Neurol 2005; 53: 197-202
93. Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004; 111: 1053-63
94. Kupsch A, Trottenberg T, Bremen D. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study. Curr Med Res Opin 2004; 20 (1): 115-20
95. Gershanik O, Emre M, Bernhard G, et al. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 963-71
96. Durif F, Devaux I, Pere JJ, et al. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. The F-01 Study Group. Eur Neurol 2001; 45: 111-8
97. Larsen JP, Worm-Petersen J, Siden A, et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003; 10: 137-46
98. Deuschl G, Vaitkus A, Fox GC, et al. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. The CAMP Study Group. Mov Disord 2007; 22: 1550-5
99. Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005; 112: 221-30
100. Fenelon G, Gimenez-Roldan S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations: a randomized, double-blind, multicentre study. J Neural Transm 2003; 110: 239-51
101. Rascol O, Brooks D, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO [Lasting effect in Adjunct therapy with Rasagiline Given Once daily] study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-54
102. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. The US01 Study Team. Arch Neurol 2004; 61: 1563-8
103. Derogatis LR. The psychosocial adjustment to illness scale (PAIS). J Psychosom Res 1986; 30 (1): 77-91
104. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49 (4): 1066-71
105. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421-8
106. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998; 55: 1089-95
107. Welsh MD, Dorflinger E, Chernik D, et al. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Mov Disord 2000; 15: 497-502
108. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-8
109. Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. The Parkinson Study Group. Mov Disord 2006; 21: 616-23
110. Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-82
111. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-20
112. Holloway RG, Shoulson I, Fahn S. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53
113. Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol 2007; 30: 72-85
114. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. EASE-PD Adjunct Study Investigators. Neurology 2007; 68: 1108-15
115. Myllyla V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand 2006; 114: 181-6
116. Korchounov A, Bogomazov G. Employment, medical absenteeism, and disability perception in Parkinson's disease: a pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. Mov Disord 2006; 21: 2220-4
117. Naimark D, Krahn MD, Naglie G, et al. Primer on medical decision analysis: part 5. Working with Markov processes. Med Decis Making 1997; 17: 152-9
118. Hudry J, Rinne JO, Keranen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother 2006; 40: 651-7
119. Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005; 21: 1005-14
120. Suchowersky O, Bailey P, Pourcher E, et al. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin Neuropharmacol 2001; 24: 214-20
121. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000; 57: 263-7
122. Lees AJ, Ratziu V, Tolosa E, et al. Safety and tolerability of adjunctive tolcapone therapy in early Parkinson's disease patients. J Neurol Neurosurg Psychiatry 2007; 78 (9): 944-8
123. Koller W, Lees A, Doder M, et al. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Tolcapone/Pergolide Study Group. Mov Disord 2001; 16: 858-66
124. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43
125. Siderowf A, Stern M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology 2006; 66 (10 Suppl. 4): S80-8
126. Nyholm D, Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-23
127. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22 (8): 1145-9
128. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease: long-term experience. Acta Neurol Scand 2001; 104 (6): 343-8
129. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43: 1698-703
130. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721-8
131. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-6
132. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. The SP 650 Study Group. Neurology 2007; 68: 1262-7
133. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49: 1060-5
134. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. The Japanese Pramipexole Study Group. Mov Disord 2003; 18: 1149-56
135. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436-41
136. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602-10
137. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. Depression/Parkinson Italian Study Group. J Neurol 2006; 253: 601-7
138. Noyes K, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Parkinson Study Group. Value Health 2006; 9: 28-38
139. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284 (15): 1931-8
140. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998; 21: 101-7
141. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. The Ropinirole Study Group. Arch Neurol 1998; 55: 1211-6
142. Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov Disord 2007; 22: 1860-5
143. Rascol O, Dubois B, Caldas AC, et al. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Parkinson REGAIN Study Group. Mov Disord 2006; 21 (12): 2110-5
144. Suwantamee J, Nidhinandana S, Srisuwananukorn S, et al. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. J Med Assoc Thai 2004; 87 (11): 1293-300
145. Evidente VG, Esteban RP, Domingo FM, et al. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience. Parkinsonism Relat Disord 2003; 10 (2): 117-21
146. Salazar Tortolero G, Wix Ramos R, Salazar Aladren P, et al. The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up [in Spanish]. Rev Neurol 2004; 38 (8): 715-9
147. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65
148. Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60
149. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-6
150. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004; 20: 131-8
151. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 307-14
152. Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006; 248: 266-70
153. Rektorova I, Rektor I, Bares M, et al. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12: 9-15
154. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103
155. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50: 357-60
156. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001; 34: 137-41
157. Bertaina-Anglade V, La Rochelle CD, Scheller DK. Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 2006; 548: 106-14
158. Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson's disease: use of the drug in the retard form. Clin Neuropharmacol 1989; 12 (1): 23-8
159. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. J Neurol 1992; 239 Suppl. 1: S28-34
160. Ziegler M, Rondot P. Action of piribedil in Parkinson disease: multicenter study [in French]. Presse Med 1999; 28 (26): 1414-8
161. Post RM, Gerner RH, Carman JS, et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35 (5): 609-15
162. Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. Parkinson Study Group TEMPO and PRESTO Investigators. J Neurol Sci 2006; 248: 78-83
163. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. UK-Irish Entacapone Study Group. J Neurol Neurosurg Psychiatry 2003; 74: 1071-9
164. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
165. Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 1999; 19: 329-35